Cargando…

Prospective Evaluation of the Feasibility of Cisplatin‐based Chemotherapy for Elderly Lung Cancer Patients with Normal Organ Functions

A study was conducted to examine the feasibility of cisplatin‐based chemotherapy in elderly patients (75 years old) with advanced non‐small cell lung cancer (NSCLC) or small cell lung cancer (SCLC). Thirty‐four patients were enrolled between September 1993 and December 1994. Patients with normal org...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oshita, Fumihiro, Kurata, Takayasu, Kasai, Takashi, Fukuda, Minoru, Yamamoto, Nobuyuki, Ohe, Yuichiro, Tamura, Tomohide, Eguchi, Kenji, Shinkai, Tetsu, Saijo, Nagahiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 1995
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920668/ https://www.ncbi.nlm.nih.gov/pubmed/8636010 http://dx.doi.org/10.1111/j.1349-7006.1995.tb03315.x

Ejemplares similares

CPT‐11: Population Pharmacokinetic Model and Estimation of Pharmacokinetics Using the Bayesian Method in Patients with Lung Cancer
por: Yamamoto, Nobuyuki, et al.
Publicado: (1994)

Subcutaneous Administration of Recombinant Human Granulocyte Colony‐stimulating Factor (KRN8601) in Intensive Chemotherapy for Patients with Advanced Lung Cancer
por: Eguchi, Kenji, et al.
Publicado: (1990)

A Pharmacokinetic and Pharmacodynamic Analysis of CPT‐11 and Its Active Metabolite SN‐38
por: Sasaki, Yasutsuna, et al.
Publicado: (1995)

Prediction from Creatinine Clearance of Thrombocytopenia and Recommended Dose in Patients Receiving (Glycolato‐O, O′)‐diammine Platinum (II) (NSC 375101D)
por: Sasaki, Yasutsuna, et al.
Publicado: (1990)

A Randomized Cross‐over Study of High‐dose Metoclopramide plus Dexamethasone versus Granisetron plus Dexamethasone in Patients Receiving Chemotherapy with High‐dose Cisplatin
por: Ohmatsu, Hironobu, et al.
Publicado: (1994)

Phase I and Pharmacokinetic Study of Paclitaxel by 24‐Hour Intravenous Infusion
por: Tamura, Tomohide, et al.
Publicado: (1994)

Rapid Polymerase Chain Reaction Assay to Detect Variation in the Extent of Gene‐specific Damage between Cisplatin‐ or VP‐16‐resistant and Sensitive Lung Cancer Cell Lines
por: Oshita, Fumihiro, et al.
Publicado: (1994)

Serial Measurement of Sister Chromatid Exchanges in the Peripheral Lymphocytes of Patients with Lung Cancer Receiving Chemotherapy in Relation to Bone Marrow Toxicity
por: Shinkai, Tetsu, et al.
Publicado: (1989)

Three Schedules of Recombinant Human Interleukin‐2 in the Treatment of Malignancy: Side Effects and Immunologic Effects in Relation to Serum Level
por: Sano, Tetsuro, et al.
Publicado: (1988)

Correlation of Gene‐specific Damage with Cisplatin between Human Adenocarcinoma Cells and Peripheral Blood Mononuclear Cells Analyzed by Polymerase Chain Reaction‐stop Assay
por: Oshita, Fumihiro, et al.
Publicado: (1995)

Inhibition of Colony Formation of Drug‐resistant Human Tumor Cell Lines by Combinations of Interleukin‐2‐activated Killer Cells and Antitumor Drugs
por: Ohtsu, Atsushi, et al.
Publicado: (1989)

Basic Design Considerations for Clinical Trials in Oncology
por: Piantadosi, Steven, et al.
Publicado: (1992)

Guidelines for Analysis and Reporting of Clinical Trials in Oncology
por: Piantadosi, Steven, et al.
Publicado: (1993)

Reversal of Cisplatin Resistance by the 1,4‐Benzothiazepine Derivative, JTV‐519
por: Nakamura, Takashi, et al.
Publicado: (2001)

Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer.
por: Ando, M., et al.
Publicado: (1997)

Phase I Study of Paclitaxel by Three‐hour Infusion: Hypotension Just after Infusion Is One of the Major Dose‐limiting Toxicities
por: Tamura, Tomohide, et al.
Publicado: (1995)

Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507
por: Sekine, I, et al.
Publicado: (2003)

Feasibility study of chemoradiotherapy followed by amrubicin and cisplatin for limited‐disease small cell lung cancer
por: Sekine, Ikuo, et al.
Publicado: (2016)

CPT‐11 Alters the Circadian Rhythm of Dihydropyrimidine Dehydrogenase mRNA in Mouse Liver
por: Shimizu, Mikiko, et al.
Publicado: (2001)

Enhanced Anti‐tumor Effect of Trastuzumab in Combination with Cisplatin
por: Naruse, Ichiro, et al.
Publicado: (2002)

Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma
por: Sekine, I, et al.
Publicado: (2004)

Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer
por: Goto, K, et al.
Publicado: (2004)

In vitro and in vivo Effects of Cisplatin and Etoposide in Combination on Small Cell Lung Cancer Cell Lines
por: Kondo, Hideki, et al.
Publicado: (1994)

Oral rehydration solution (OS-1) as a substitute of intravenous hydration after cisplatin administration in patients with lung cancer: a prospective multicenter trial
por: Horinouchi, Hidehito, et al.
Publicado: (2018)

Five‐year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non‐small‐cell lung cancer
por: Kanda, Shintaro, et al.
Publicado: (2020)

Alteration of Type II Regulatory Subunit of cAMP‐dependent Protein Kinase in Human Cisplatin‐resistant Cells as a Basis of Collateral Sensitivity to 8‐Chloro‐cAMP
por: Nishio, Kazuto, et al.
Publicado: (1992)

Determinants of Drug Response in a Cisplatin‐resistant Human Lung Cancer Cell Line
por: Fujiwara, Yasuhiro, et al.
Publicado: (1990)

CORRECTION
por: Tatsumi, Yasuaki, et al.
Publicado: (2001)

Enhancement of in vivo Antitumor Activity of a Novel Antimitotic 1‐Phenylpropenone Derivative, AM‐132, by Tumor Necrosis Factor‐cc or Interleukin‐6
por: Tatsumi, Yasuaki, et al.
Publicado: (2001)

Reversal of Cisplatin Resistance with Amphotericin B in a Non‐small Cell Lung Cancer Cell Line
por: Morikage, Toshihiko, et al.
Publicado: (1991)

Present Status and Problems on Molecular Targeted Therapy of Cancer
por: Saijo, Nagahiro
Publicado: (2012)

The Role of Pharmacoethnicity in the Development of Cytotoxic and Molecular Targeted Drugs in Oncology
por: Saijo, Nagahiro
Publicado: (2013)

Highlights for ESMO 40: celebration review for lifetime achievement awards
por: Saijo, Nagahiro
Publicado: (2016)

Interferon‐γ‐inducing Factor Gene Transfection into Lewis Lung Carcinoma Cells Reduces Tumorigenicity in vivo
por: Fukumoto, Hisao, et al.
Publicado: (1997)

Effect of Glutathione Depletion on Cisplatin Resistance in Cancer Cells Transfected with the γ‐Glutamylcysteine Synthetase Gene
por: Kurokawa, Hirokazu, et al.
Publicado: (1997)

Enhancement of Cisplatin Sensitivity in High Mobility Group 2 cDNA‐transfected Human Lung Cancer Cells
por: Arioka, Hitoshi, et al.
Publicado: (1999)

Reduction in nephrotoxicities using short hydration for chemotherapy containing cisplatin: a consecutive analysis of 467 patients with thoracic malignancies
por: Tanaka, Midori, et al.
Publicado: (2018)

Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer
por: Hirahara, Noriyuki, et al.
Publicado: (2021)

Intracellular Carboxyl Esterase Activity Is a Determinant of Cellular Sensitivity to the Antineoplastic Agent KW‐2189 in Cell Lines Resistant to Cisplatin and CPT‐11
por: Ogasawara, Hayato, et al.
Publicado: (1995)

Cisplatin inhibits MEK1/2
por: Yamamoto, Tetsu, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_u5bumom5ebhskrmlnbk72g69n0